Medway Community Healthcare Medway NHS Trust Foundation Trust
Medway Clinical Commissioning Group Swale Clinical Commissioning Group
Online Formulary

2. Cardiovascular system - guidance

To access BNF Formulary section click on the link under BNF Section/s

To access the Guidance Document click on the highlighted text under the Title column

Use documents past their review date with Caution

 

BNF Section/s Title Issuing Body  Date of Issue/Review Update Due
2.3.2.3 Andexanet alfa - Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban  - TA697  NICE  12 May 2021  

2.3.2 & 2.3.2.2 & Edoxaban

 Anticoagulant prescribing - KMCCG Joint Prescribing Committee (JPC) Position Statement and Risk Mitigation Principles for anticoagulant prescribing  Kent and Medway  CCG Jun 2022 Jun 24
2.3.2.2 Apixaban - Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults TA245  NICE Jan 2012  - 
2.3.2 & 2.3.2.2
 Atrial fibrillation - Atrial fibrillation: diagnosis and management NG196 NICE  Jun 2021  - 
2.6 Bempedoic Acid/Ezetimibe - BEMPEDOIC ACID WITH EZETIMIBE (Nilemdo and Nustendi) for treating primary hypercholesterolemia or mixed dyslipidaemia. Implementation guidance for Nice TA694  Kent and Medway  CCG Sep 2021
Sep 2022
2.3.2.5 Dabigatran etexilate -Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults - TA157  NICE Sept 2008  - 
2.3.2.5 Dabigatran etexilate - Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation  TA249  NICE Jul 2021  - 
2.5.3 Dapagliflozin & Empagliflozin - K&M Implementation of NICE TA’s – SGLT2 inhibitors (Dapagliflozin & Empagliflozin) in the treatment of chronic heart failure Kent and Medway  ICB Aug 2023 Aug 2025
2.5.3 Dapagliflozin - Dapagliflozin for treating chronic heart failure with reduced ejection fraction TA679  NICE Feb 2021  -
2.5.3 Dapagliflozin - Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction TA902 NICE Jun 2023  -
2.5.3
6.3.1.4		 Dapagliflozin - Dapagliflozin for treating chronic kidney disease TA775 NICE Mar 2022  - 

2.5.3 6.3.1.4

 Dapagliflozin - Primary Care Guidance Dapagliflozin for Chronic Kidney Disease (CKD) in Adults Kent and Medway  CCG Jun 2022  - 

2.3.2.2

 DOAC -  Direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in patients with renal impairment MHRA
Drug Safety Update		 May 2023  -

2.3.2.2

2.3.2.5

 DOAC Monitoring - DOAC Monitoring Recommendations for Non-Valvular Atrial Fibrillation (NVAF) in Primary Care Kent and Medway  CCG Dec 2021 Dec 2023
2.5.3 Empagliflozin - Empagliflozin for treating chronic heart failure with reduced ejection fraction TA773 NICE Mar 2022  - 

2.5.3

 Empagliflozin - Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction TA929
 NICE Nov 2023  

2.3.1

  Epoprostenol   High-Cost Drugs    

2.5.1  6.3.1.4

 Finerenone - Finerenone for treating chronic kidney disease in type 2 diabetes TA877
 NICE Mar 2023  
2.6 Icosapent  -  Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides TA805 NICE 13 July 2022  
2.6 Inclisiran - Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia TA733​ NICE Oct 2021 2024
2.6 Inclisiran - Kent & Medway ICB Position Statement
Prescribing Inclisiran (Leqvio®) for the treatment of primary hypercholesterolaemia or mixed dyslipidaemia in Kent and Medway		 Kent and Medway  ICB Jul 2023 Jul 2025
2.6 Lipid Management - Summary of National Guidance for Lipid Management for
Primary and Secondary Prevention of CVD		 NICE /National Guidance Nov 2022 -
2.3.2.2 Rivaroxaban - Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults - TA170 NICE Apr 2009  - 
2.3.2.2 Rivaroxaban - Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (PE)  TA261 NICE Jul 2012  -
2.5.2 Sacubitril + Valsartan - Sacubitril + Valsartan prescribing Guidance   MCH/Medway & Swale CCG Sep 2016  -
2.3.2.6 Warfarin - Guidance for switching from Warfarin to DOACs -  Kent and Medway  CCG Jun 2020  -
         

 

 

 

 

 

 

 

 

 

  • First Line Choice
  • On Formulary
  • Specialist Initiation Only
  • Hospital Only
  • KMPT Initiation Only
  •